Marshall Wace LLP Sells 38,676 Shares of Boston Scientific Corporation (BSX)

Marshall Wace LLP cut its position in shares of Boston Scientific Corporation (NYSE:BSX) by 59.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,882 shares of the medical equipment provider’s stock after selling 38,676 shares during the period. Marshall Wace LLP’s holdings in Boston Scientific Corporation were worth $725,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Guardian Life Insurance Co. of America increased its stake in Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 49 shares during the last quarter. First Personal Financial Services increased its stake in Boston Scientific Corporation by 0.9% in the first quarter. First Personal Financial Services now owns 9,107 shares of the medical equipment provider’s stock worth $226,000 after buying an additional 80 shares during the last quarter. Cleararc Capital Inc. increased its stake in Boston Scientific Corporation by 0.8% in the first quarter. Cleararc Capital Inc. now owns 33,322 shares of the medical equipment provider’s stock worth $829,000 after buying an additional 251 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 338 shares during the last quarter. Finally, Checchi Capital Advisers LLC increased its stake in Boston Scientific Corporation by 2.6% in the first quarter. Checchi Capital Advisers LLC now owns 13,553 shares of the medical equipment provider’s stock worth $337,000 after buying an additional 349 shares during the last quarter. Institutional investors own 91.62% of the company’s stock.

Boston Scientific Corporation (NYSE BSX) opened at 27.21 on Wednesday. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $28.51. The stock has a market cap of $37.34 billion, a PE ratio of 48.68 and a beta of 1.09. The firm has a 50-day moving average of $27.14 and a 200 day moving average of $26.19.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the firm posted $0.27 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Analysts anticipate that Boston Scientific Corporation will post $1.26 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Marshall Wace LLP Sells 38,676 Shares of Boston Scientific Corporation (BSX)” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://sportsperspectives.com/2017/08/23/marshall-wace-llp-sells-38676-shares-of-boston-scientific-corporation-bsx.html.

A number of analysts have recently issued reports on the stock. J P Morgan Chase & Co restated an “overweight” rating and set a $31.00 price target (up previously from $27.00) on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Zacks Investment Research downgraded shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Royal Bank Of Canada restated a “buy” rating and set a $31.00 price target on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. Wells Fargo & Company restated an “outperform” rating and set a $31.00 price target (up previously from $29.50) on shares of Boston Scientific Corporation in a report on Friday, June 16th. Finally, BidaskClub upgraded shares of Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. Six equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Boston Scientific Corporation presently has an average rating of “Buy” and a consensus target price of $30.06.

In other news, SVP John Bradley Sorenson sold 7,900 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $26.37, for a total value of $208,323.00. Following the sale, the senior vice president now owns 21,680 shares in the company, valued at $571,701.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Wendy Carruthers sold 12,433 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $26.75, for a total transaction of $332,582.75. The disclosure for this sale can be found here. In the last three months, insiders sold 207,625 shares of company stock worth $5,686,383. Insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply